Skip to main content

Table 2 Overall resistance pattern of the total No. of collected isolates with the antibiotics

From: Surfactant nanovesicles for augmented antibacterial activity against carbapenemase resistant enterobacteriaceae and extended spectrum beta-lactamases producing bacteria: in vitro and in vivo evaluation

Antibiotics

Total No. of resistant E. coli isolates(N = 36)

Total No. of resistant K. pneumoniae isolates(N = 74)

Ampicillin (AMP)

36 (100%)

74 (100%)

Ampicillin/Sulbactam (AMA)

23 (63.89)

64 (86.49%)

Piperacillin/Tazobactam (TZP)

6 (16.67%)

52 (70.27%)

Cefazolin (CZ)

36 (100%)

74 (100%)

Cefoxitin (FOX)

20 (55.56%)

51(68.92%)

Ceftazidime (CAZ)

36 (100%)

73 (98.65%)

Ceftriaxone (CRO)

36 (100%)

74 (100%)

Cefepime (FEP)

33 (91.67%)

73 (98.65%)

Meropenem (MEM)

3 (8.33%)

47 (63.51%)

Ertapenem (ERT)

3 (8.33%)

52 (70.72%)

Amikacin (AMK)

2 (5.56%)

41 (55.41%)

Gentamicin (GN)

15 (41.67%)

45 (60.81%)

Tobramycin (TOB)

12 (33.33)

50 (67.57%)

Ciprofloxacin (CIP)

28 (77.78%)

56 (75.68%)

Levofloxacin (LVX)

29 (80.56%)

56 (75.68%)

Nitrofurantoin (NIF)

3 (8.33%)

52 (70.27%)

Sulfamethoxazole/trimethoprim (SXT)

20 (55.56%)

67 (90.54%)

Tigecycline (TGI)

1 (2.78%)

10 (13.51%)